The effect of exercise training modality on serum brain derived neurotrophic factor levels in individuals with type 2 diabetes
- PMID: 22880108
- PMCID: PMC3412800
- DOI: 10.1371/journal.pone.0042785
The effect of exercise training modality on serum brain derived neurotrophic factor levels in individuals with type 2 diabetes
Abstract
Introduction: Brain derived neurotrophic factor (BDNF) has been implicated in memory, learning, and neurodegenerative diseases. However, the relationship of BDNF with cardiometabolic risk factors is unclear, and the effect of exercise training on BDNF has not been previously explored in individuals with type 2 diabetes.
Methods: Men and women (N = 150) with type 2 diabetes were randomized to an aerobic exercise (aerobic), resistance exercise (resistance), or a combination of both (combination) for 9 months. Serum BDNF levels were evaluated at baseline and follow-up from archived blood samples.
Results: Baseline serum BDNF was not associated with fitness, body composition, anthropometry, glucose control, or strength measures (all, p>0.05). Similarly, no significant change in serum BDNF levels was observed following exercise training in the aerobic (-1649.4 pg/ml, CI: -4768.9 to 1470.2), resistance (-2351.2 pg/ml, CI:-5290.7 to 588.3), or combination groups (-827.4 pg/ml, CI: -3533.3 to 1878.5) compared to the control group (-2320.0 pg/ml, CI: -5750.8 to 1110.8). However, reductions in waist circumference were directly associated with changes in serum BDNF following training (r = 0.25, p = 0.005).
Conclusions: Serum BDNF was not associated with fitness, body composition, anthropometry, glucose control, or strength measures at baseline. Likewise, serum BDNF measures were not altered by 9 months of aerobic, resistance, or combination training. However, reductions in waist circumference were associated with decreased serum BDNF levels. Future studies should investigate the relevance of BDNF with measures of cognitive function specifically in individuals with type-2 diabetes.
Trial registration: ClinicalTrials.gov NCT00458133.
Conflict of interest statement
Figures
References
-
- Kaplan GB, Vasterling JJ, Vedak PC (2010) Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behavioural Pharmacology 21: 427–437. - PubMed
-
- Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery 10: 209–219. - PubMed
-
- Lee B-H, Kim H, Park S-H, Kim Y-K (2007) Decreased plasma BDNF level in depressive patients. Journal of Affective Disorders 101: 239–244. - PubMed
-
- Connor B, Young D, Yan Q, Faull RLM, Synek B, et al. (1997) Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Molecular Brain Research 49: 71–81. - PubMed
-
- Krabbe KS, Mortensen EL, Avlund K, Pedersen AN, Pedersen BK, et al. (2009) Brain-Derived Neurotrophic Factor Predicts Mortality Risk in Older Women. Journal of the American Geriatrics Society 57: 1447–1452. - PubMed